Guided Therapeutics (GTHP) Gains from Investment Securities (2011 - 2025)

Guided Therapeutics has disclosed Gains from Investment Securities across 15 years of filings, most recently posting $12000.0 for Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at $12000.0, up 71.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $65000.0 (down 82.94% YoY), and the FY2025 annual result was $33000.0, down 98.86% from the prior year.
• Gains from Investment Securities came in at $12000.0 for Q4 2025 at Guided Therapeutics, down from $2.8 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $3.1 million in Q2 2025 to a low of -$151000.0 in Q2 2022.
• The 5-year median for Gains from Investment Securities is $187000.0 (2022), against an average of $1.1 million.
• Across the five-year window, Gains from Investment Securities slumped 15200.0% in 2022 and soared 102400.0% in 2023, its largest moves.
• Guided Therapeutics' Gains from Investment Securities stood at $34000.0 in 2021, then soared by 864.71% to $328000.0 in 2022, then plunged by 85.98% to $46000.0 in 2023, then plunged by 84.78% to $7000.0 in 2024, then jumped by 71.43% to $12000.0 in 2025.
• The last three Gains from Investment Securities figures came in at $12000.0 (Q4 2025), $2.8 million (Q3 2025), and $3.1 million (Q2 2025), per Business Quant data.